Supporting safe practices for low-dose methotrexate – NMS 2021


Inconsistent practices and information about the use of low-dose methotrexate for inflammatory diseases results in unfounded patient and health professional concerns, which can influence therapy decisions and adherence.

CATAG developed a Position Statement relating to best practice use of low-dose methotrexate in hospitals for DTCs and clinicians.

This was presented as a lightning talk at the National Medicines Symposium 2021.

This work was funded by the Australian Government Department of Health through the Value in Prescribing – bDMARDs Program Grant. 


Download resource

Download (8.15 MB, MP4)

Published date

3 May 2021

Resource type


Governance topic

Low-dose methotrexate